SEARCH

SEARCH BY CITATION

References

  • 1
    Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yosizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. HEPATOLOGY 1990; 12: 671675.
  • 2
    Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. HEPATOLOGY 1998; 27: 13941402.
  • 3
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and non-cirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174181.
  • 4
    Tanaka H, Tsukuma H, Kasahara A, Kawazuma Y, Shimoji S, Kinoshita N, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 741749.
  • 5
    Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. HEPATOLOGY 1999; 29: 11241130.
  • 6
    Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study of 1146 patients. J Hepatol 1999; 30: 653659.
  • 7
    Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 12731280.
  • 8
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 9
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 10
    Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon Alpha-2a plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38: 645652.
  • 11
    Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr, et al. Predicting sustained virologic responses in chronic hepatitis C patients treated with peginterferon alpha-2a ribavirin. J Hepatol 2005; 43: 425433.
  • 12
    Carlsson T, Reichard O, Norkrans G, Bläckberg J, Sangfelt P, Wallmark E, et al. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virologic response. J Viral Hepatol 2005; 12: 473480.
  • 13
    Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 7781.
  • 14
    Vrolijk JM, Kwekkeboom J, Janssen HL, Hansen BE, Zondervan PE, Osterhaus AD, et al. Pretreatment intra-hepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C infection. J Infect Dis 2003; 188: 15281532.
  • 15
    Masaki N, Fukushima S, Hayashi S. Lower Th-1/Th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 21632169.
  • 16
    Marinho RT, Pinto RM, Santos ML, de Moura MC. Lymphocyte T helper-specific reactivity in sustained responders to interferon and ribavirin with negativization (seroreversion) of anti-hepatitis C virus. Liver Int 2004; 24: 413418.
  • 17
    Trapero M, García-Buey L, Muñoz C, Vitón M, Moreno-Monteagudo JA, Borque MJ, et al. Maintenance of T1 response as induced during PEG-IFNα plus ribavirin therapy controls viral replication in genotype-1 patients with chronic hepatitis C. Rev Esp Enferm Dig 2005; 97: 481490.
  • 18
    Kobayashi K, Ueno Y, Kobayashi Y, Akahane T, Satoh S, Kikuchi K, et al. Th1 response during ribavirin and interferon-α2b combination therapy in chronic hepatitis C. Hepatol Res 2006; 34: 104110.
  • 19
    Tarantino G, Conca P, Sorrentino P, Ariello M. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. J Gastroenterol Hepatol 2006; 21: 12661268.
  • 20
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki S, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403410.
  • 21
    Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alpha-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepatol 2006; 13: 371376.
  • 22
    Missiha S, Heathcote J, Arenovich T, Khan K. Canadian Pegasys Expanded Access Group: impact of asian race on response to combination therapy with peginterferon alpha-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 21812188.
    Direct Link:
  • 23
    Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201207.
  • 24
    Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, et al. Ribavirin and interferon alpha-2b in chronic hepatitis C: assessment of possible pharmaco kinetic and pharmaco dynamic interactions. Br J Clin Pharmacol 1998; 46: 563570.
  • 25
    Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepa-titis. Proc Natl Acad Sci U S A 1990; 87: 95249528.
  • 26
    Kawakami Y, Nabeshima S, Furusyo N, Sawayama Y, Hayashi J, Kashiwagi S. Increased frequency of interferon-gamma producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95: 227232.
  • 27
    Paterson M, Laxton CD, Thomas HC, Ackrill AM, Foster GR. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response. Gastroenterology 1999; 117: 11871197.
  • 28
    Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217227.
  • 29
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictive factors of virologic non-response to interferon ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load. J Med Virol 2006; 78: 8390.
  • 30
    Pascu M, Martus P, Höhne M, Wiedenmann B, Hopf U, Schreier E, et al. Sustained virologic response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004; 53: 13451351.
  • 31
    Lee S, Macquillan GC, Keane NM, Flexman J, Jeffrey GP, French MA, et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol Cell Biol 2002; 80: 391397.
  • 32
    Lagging M, Romero A, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. HEPATOLOGY 2006; 44: 16171625.
  • 33
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b in combination with ribavirin compared to interferon alpha2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet 2001; 358: 958965.
  • 34
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for non response to antiviral treatment in chronic hepatitis C. HEPATOLOGY 2003; 38: 639644.
  • 35
    Shinohara M, Ishii K, Takamura N. Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response or no response to IFN. Hepatol Res 2003; 27: 260265.